Plus Therapeutics Inc

Plus Therapeutics Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2746
  • Today's Change0.007 / 2.65%
  • Shares traded98.29k
  • 1 Year change-72.06%
  • Beta0.4119
Data delayed at least 15 minutes, as of Mar 27 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company develops a targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. Its lead radiotherapeutic candidate, Rhenium (186Re) obisbemeda is designed specifically to CNS cancers including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. The Company’s portfolio also includes 188RNL-BAM, a radioembolization therapy for liver cancer.

  • Revenue in USD (TTM)224.00k
  • Net income in USD-20.28m
  • Incorporated1997
  • Employees17.00
  • Location
    Plus Therapeutics Inc4200 Marathon Blvd Ste 200AUSTIN 78756-3433United StatesUSA
  • Phone+1 (858) 458-0900
  • Fax+1 (302) 636-5454
  • Websitehttp://www.plustherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Nexgel Inc2.06m-5.74m9.05m10.00--1.10--4.40-1.03-1.030.36931.470.25455.238.99205,800.00-70.94---90.70--16.08---278.77--7.10-1.570.0333--130.12---90.37------
Aptinyx Inc0.00-72.41m9.14m40.00--0.1874-----1.07-,506.55---32.830.3362---36.06-36.64-49.61------
Lucira Health Inc212.13m-143.28m9.14m221.00--0.1496--0.0431-3.59-3.595.271.511.034.9916.131,504,497.00-69.56---94.88---16.03---67.54--0.7858-87.120.3257--34,492.94---73.58------
China Health Industries Holdings, Inc.32.65k713.81k9.18m45.0012.840.21836.11281.030.01090.01090.00050.64130.00060.0481.12725.561.393.151.643.829.1962.712,186.2523.186.68--0.1189---100.00-86.65-127.41------
Halberd Corp281.24k25.34k9.22m3.007.03--363.5732.800.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Novelstem International Corp424.75k6.25m9.38m15.000.72510.14891.4822.070.27580.27580.01881.340.0146--21.58--21.53-9.0222.48-12.13----1,472.13-168.94----0.0011---31.09-41.39580.92------
Navidea Biopharmaceuticals Inc65.66k-17.22m9.38m11.00------142.89-0.5576-0.55760.0021-0.26240.0119-------275.54-169.68---753.52-181.6891.34-23,114.79-1,938.53---12.79-----87.65-48.49-46.75------
Aptevo Therapeutics Inc6.78m5.58m9.47m54.001.740.60071.441.401.071.241.363.100.1417--4.38125,537.0011.66-51.8720.10-75.99----82.31-349.18----0.1988--
Virpax Pharmaceuticals Inc0.00-21.65m9.59m7.00--0.5786-----1.85-1.850.001.420.00----0.00-73.09---80.09--------------0.00-------79.58------
Cyclo Therapeutics Inc1.77m-13.26m9.60m9.00--1.37--5.41-1.62-1.620.21740.66380.18120.78864.73197,120.00-135.45-114.25-199.60-174.7388.3389.97-747.59-676.152.83--0.00--75.541.08-59.78--19.22--
Plus Therapeutics Inc224.00k-20.28m9.73m17.00--1.43--43.42-0.787-0.7870.00850.19180.0098----13,176.47-88.44-53.03-144.17-121.85-----9,051.34-407.87---35.010.4556-----48.87-51.32---19.40--
Theriva Biologics Inc0.00-19.70m9.98m16.00--0.1801-----1.35-1.350.003.670.00----0.00-25.17-38.93-27.61-47.48------------0.0044-------84.67---52.33--
Imunon Inc500.00k-26.89m10.04m29.00--0.2318--20.07-4.28-4.280.0785.830.0071--14.5117,241.38-38.41-41.05-43.00-48.59-----5,377.37-3,655.60---4.930.1265--
Galmed Pharmaceuticals Ltd0.00-22.68m10.08m19.00--0.6403-----0.903-0.9030.000.62490.00----0.00-69.60-39.00-84.33-43.35-------3,325.46----0.00-------12.85---8.34--
Neximmune Inc0.00-61.14m10.30m74.00--0.2159-----2.64-2.640.001.830.00----0.00-75.38---84.10--------------0.00-------54.70------
Context Therapeutics Inc0.00-14.84m10.31m9.00--0.2966-----0.9292-0.92920.002.180.00----0.00-33.24---35.74--------------0.00-------41.88------
Data as of Mar 27 2023. Currency figures normalised to Plus Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

7.60%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 20221.09m3.25%
Parkman Healthcare Partners LLCas of 31 Dec 2022583.47k1.74%
Geode Capital Management LLCas of 31 Dec 2022258.05k0.77%
Schonfeld Strategic Advisors LLCas of 31 Dec 2022190.40k0.57%
Millennium Management LLCas of 31 Dec 2022136.90k0.41%
BlackRock Fund Advisorsas of 31 Dec 2022104.43k0.31%
Renaissance Technologies LLCas of 31 Dec 202278.37k0.23%
Two Sigma Securities LLCas of 31 Dec 202240.75k0.12%
SSgA Funds Management, Inc.as of 31 Dec 202234.41k0.10%
Great Valley Advisor Group, Inc.as of 31 Dec 202233.60k0.10%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.